Stockreport

Axsome Therapeutics eyes approval after Phase III narcolepsy win [Yahoo! Finance]

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com
PDF AXS-12 (reboxetine), the norepinephrine reuptake inhibitor and cortical dopamine modulator achieved the primary endpoint in the ENCORE trial (NCT05059223), reducing the [Read more]